You are here

  • Home
  • Archive
  • Volume 11, Issue 9
  • Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma

 

Online download statistics by month:

Online download statistics by month: September 2023 to August 2025

AbstractFullPdf
Sep 202314314321
Oct 2023580585222
Nov 202334034084
Dec 202324825079
Jan 202416917095
Feb 202418518777
Mar 2024262262135
Apr 2024285290103
May 2024268270107
Jun 202418018081
Jul 202423323493
Aug 202418718655
Sep 202418018177
Oct 202418018087
Nov 202420020199
Dec 202415415543
Jan 202518518596
Feb 202525825961
Mar 2025172173139
Apr 202515415483
May 202513913980
Jun 2025919446
Jul 2025110
Aug 2025110
Total479548201963